Bausch + Lomb Expands OTC Eye Care Portfolio, Acquires JNJ's Blink

Bausch + Lomb Corporation BLCO has acquired Johnson & Johnson's JNJ eye and contact lens drops brand Blink for $106.5 million to bolster its position in over-the-counter (OTC) consumer products for eye care.

The deal marks its second in two weeks to bolster the contact lens maker's portfolio of eye care products.

The Blink portfolio of eye drops consists of various eye drops and contact lens rewetting drops that provide immediate and long-lasting symptom relief. 

According to a 2022 Gallup Study, 57% of American adults report eye dryness, and nearly half (48%) use OTC lubricant drops for relief.

Also Read: Inflationary Factors And Slow Product Uptake Could Be Headwinds For Bausch + Lomb, Analyst Says.

Last week, Bausch + Lomb struck a $1.75 billion deal with Swiss drugmaker Novartis AG NVS to buy several eye-care products, including anti-inflammation eye drop Xiidra.

In May, the FDA approved Bausch + Lomb's Miebo for dry-eye condition, which affects about 739 million people worldwide, including around 38 million in the United States, Reuters reported.

The report citing Morningstar analyst added that the global dry eye disease market is expected to be worth around $5 billion.

Price Action: BLCO shares are down 1.42% at $19.50 on the last check Thursday.

Photo via Wikimedia Commons

Market News and Data brought to you by Benzinga APIs
Posted In: M&ANewsHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!